Previous 10 | Next 10 |
The following healthcare companies have filed for mixed shelf offerings: More news on: Citius Pharmaceuticals, Inc., Flexion Therapeutics, Inc., SCYNEXIS, Inc., Healthcare stocks news, , Read more ...
-Engaging with patient community and presenting overview of PRESIDIO study at The Myositis Association’s (TMA) International Annual Patient Conference -Scientific poster presentation on MISSION Phase 1b study data at 22 nd Pan-American Congress of Rheumatology 2020 (PANLAR 2020...
Introduction 2019 was a good year for lupus patients, as multiple companies reported positive results of their late-stage clinical trials. However, this is not necessarily positive news for Kezar Life Sciences ( KZR ). The company is currently developing a cure for rare inflammatory dise...
Kezar Life Sciences, Inc. (KZR) Q2 2020 Earnings Conference Call August 5, 2020 16:30 ET Company Participants Celia Economides - Senior Vice President of Strategy & External Affairs John Fowler - Chief Executive Officer Noreen Henig - Chief Medical Officer Christopher Kirk ...
The following slide deck was published by Kezar Life Sciences, Inc. in conjunction with their 2020 Q2 earnings Read more ...
Kezar Life Sciences (NASDAQ: KZR ) : Q2 GAAP EPS of -$0.22 beats by $0.04 . More news on: Kezar Life Sciences, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
Conference call and webcast today at 4:30pm EDT Kezar Life Sciences, Inc. (Nasdaq: KZR ), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced its second quarter 2020 financial results ...
Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer, today announced members of the executive team will present during upcoming virtual investor conferences...
Conference Call and webcast to follow Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer today announced that it will release its second quarter fin...
2 Small Cap Stocks To Watch Before Friday Like it or not, small-cap stocks have emerged as a popular asset class to watch this quarter. More specifically, small-cap biotech stocks are making big moves like never before. For this reason, it is gathering a lot of gamblers and crypto traders ...
News, Short Squeeze, Breakout and More Instantly...
Kezar Life Sciences Inc. Company Name:
KZR Stock Symbol:
NASDAQ Market:
Kezar Life Sciences Inc. Website:
Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer, today announced that Chris Kirk, Co-founder and Chief Executive Officer, will participate in a fireside chat at...
PALIZADE Phase 2b clinical trial of zetomipzomib in patients with active lupus nephritis actively enrolling; reiterating guidance of topline data in mid-2026 PORTOLA Phase 2a clinical trial of zetomipzomib in patients with autoimmune hepatitis actively enrolling; reiterating guidance of t...
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...